Patent · US Active

Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

US9388141B2 · kind B2 · utility

0Cited by

1References

27Claims

0Family size

Assignees

Abb Vie Inc. · US
Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

Andreas Haupt · Ludwigshafen, DE
Jurgen Dinges · Wadsworth, US
Liliane Unger · Ludwigshafen, DE
Karsten Wicke · Ludwigshafen, DE
Robert Van Waterschoot · Riehen, CH
Karla Drescher · Ludwigshafen, DE
Ana-Lucia Relo · Ludwigshafen, DE

Key dates

Filing date	Mar 14, 2014
Grant date	Jul 12, 2016
Priority date	—
Expiry date	Mar 14, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.In formula I, the variables have the following meanings:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.